NCT03648489 2024-09-20
DICE
Imperial College London
Phase 2 Completed
Clinical Trials
6 trialsNCT03097328 2024-04-29
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03193853 2023-08-07
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase 2 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown